secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001178670-25-000076
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions
------------------------------------------------------------------------

- Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.
- Kevin Fitzgerald's role expanded to include external innovation; receives one-time RSU grant of $2.5M.
- Garg's base salary set at $825,000 with STI target of 65% of base; LTI target to be determined.
- Fitzgerald's STI target increased to 60% of base salary.
- Alnylam targets delivering RNAi therapeutics to all major tissues by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000076/0001178670-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000076/alny-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer